Intelligence Feed event · Equity · 2026-10-07

    Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout

    Question

    Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present updated details on Licaminlimab at the Eyecelerator symposium during the American Academy of Ophthalmology 2026 meeting on October 8. Licaminlimab represents a novel topical anti-TNF alpha biologic engineered for TNFR1-mediated dry eye disease. Management confirmed that the pivotal PREDICT-1 registrational trial is positioned to deliver topline readout data before year-end.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-presents-dry-eye-candidate-licaminlimab-ahead-of-year-end-phase-3-readout-99855a

    EQUITY
    Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present updated details on Licaminlimab at the Eyecelerator symposium during the American Academy of Ophthalmology 2026 meeting on October 8. Licaminlimab represents a novel topical anti-TNF alpha biologic engineered for TNFR1-mediated dry eye disease. Management confirmed that the pivotal PREDICT-1 registrational trial is positioned to deliver topline readout data before year-end.
    OCS
    Impact
    56
    OCT 7
    SIG
    85%
    OCS
    Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present updated details on Licaminlimab at the Eyecelerator symposium during the American Academy of Ophthalmology 2026 meeting on October 8. Licaminlimab represents a novel topical anti-TNF alpha biologic engineered for TNFR1-mediated dry eye disease. Management confirmed that the pivotal PREDICT-1 registrational trial is positioned to deliver topline readout data before year-end.
    → Clinical conference exposure and confirmation of late-stage trial milestones shift biotech speculative valuation ahead of binary Phase 3 data releases.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present updated details on Licaminlimab at the Eyecelerator symposium during the American Academy of Ophthalmology 2026 meeting on October 8. Licaminlimab represents a novel topical anti-TNF alpha biologic engineered for TNFR1-mediated dry eye disease. Management confirmed that the pivotal PREDICT-1 registrational trial is positioned to deliver topline readout data before year-end.
    Affected
    OCS
    Transmission
    Clinical conference exposure and confirmation of late-stage trial milestones shift biotech speculative valuation ahead of binary Phase 3 data releases.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech pipeline valuation repricing on Phase 3 binary outcome timelineUp1-3mPREDICT-1 registrational trial topline data scheduled for year-end 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month